Amarantus BioScience Holdings, Inc.
Amarantus BioScience Holdings, Inc. (AMBS) Revenue
Annual & quarterly revenue history · segment & region breakdown
AMBS · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsAmarantus BioScience Holdings, Inc. trailing twelve-month (TTM) revenue is $0.00B, an increase of 0.00% year-over-year from $0.00B in FY2022.
Revenue trend
2022 – 2007 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2022-12-31 | $0.00B | +$0.00B | — |
| 2021-12-31 | $0.00B | -$0.00B | -100.00% |
| 2020-12-31 | $0.00B | -$0.02B | -99.63% |
| 2019-12-31 | $0.02B | +$0.02B | — |
| 2018-12-31 | $0.00B | +$0.00B | — |
| 2017-12-31 | $0.00B | +$0.00B | — |
| 2016-12-31 | $0.00B | +$0.00B | — |
| 2015-12-31 | $0.00B | +$0.00B | — |
| 2014-12-31 | $0.00B | +$0.00B | — |
| 2013-12-31 | $0.00B | +$0.00B | — |
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Amarantus BioScience Holdings, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Amarantus BioScience Holdings, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Amarantus BioScience Holdings, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
AMBS revenue · 4 questionsAMBS's trailing twelve-month (TTM) revenue is $0.00B. That is an increase of 0.00% year-over-year from $0.00B in FY2022.
▸ Source: FMP · Amarantus BioScience Holdings, Inc. SEC filings · GAAP · Amarantus BioScience Holdings, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026